IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Performance
Performance Report
Performance Report
Fabino Life Sciences IPO is a Fixed Price listing on BSE SME exchange, with an ipo size of ₹ 3.24 Cr. The company is based in New Delhi and caters to Pharmaceutical sector. Aryaman Financial Services is the merchant banker of Fabino Life Sciences IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 26th November 2021.
Fabino Life Sciences IPO posted revenues of ₹ 4.52 crores and PAT of ₹ 0.04 crores in FY22 on annualised basis.
Revenue:
₹ 4.52 Cr.
EBITDA Margin:
2.65
% 
Net Worth: ₹ 1.32 Cr.
Market Capitalisation:
₹ 7.56 Cr.
P/E:
133.00 times
P/BV: 1.66 times
EV/EBITDA: 65.50 times
Financial results of Fabino Life Sciences IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Jun-21 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 2.81 | 2.25 | 3.59 | 8.55 | |
| Net Worth | 1.32 | 1.30 | 0.67 | 0.60 | |
| Total Debt | 0.42 | 0.31 | 1.08 | 2.52 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
1.13
4.52 |
3.06 | 7.52 | 2.76 | |
EBITDA
EBITDA on annualised basis |
0.03
0.12 |
0.07 | 0.32 | 0.32 | |
PAT
PAT on annualised basis |
0.01
0.04 |
0.03 | 0.07 | [●] | |
Fabino Life Sciences IPO PAT Margin is 0.88 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Fabino Life Sciences IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Jun-21 | FY21 | FY20 | FY19 |
|---|---|---|---|---|
| EBITDA Margin (%) | 2.65 | 2.29 | 4.26 | 11.59 |
| PAT Margin (%) | 0.88 | 0.98 | 0.93 | [●] |
| EPS (₹) | 0.12 | 0.50 | 1.15 | [●] |
| ROE (%) | 0.76 | 2.31 | 10.45 | [●] |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 0.36 | 1.33 | 1.95 | [●] |
| Debt to Equity | 0.32 | 0.24 | 1.61 | 4.20 |
The market Capitalisation of Fabino Life Sciences IPO is ₹ 7.56 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Fabino Life Sciences IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Fabino Life Sciences IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Fabino Life Sciences IPO is ₹ 7.56 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Fabino Life Sciences IPO has a Price-to-Earnings (PE) ratio of 133.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Fabino Life Sciences IPO reported revenue of ₹ 4.52 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Fabino Life Sciences IPO provide insights into sales growth, market demand, and business scalability.
Fabino Life Sciences recorded an EBITDA of ₹ 0.12 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Fabino Life Sciences Profit After Tax (PAT) is ₹ 0.04 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 4.52 Cr.
EBITDA Margin:
2.65
%
Net Worth: ₹ 1.32 Cr.
Market Capitalisation:
₹ 7.56 Cr.
P/E:
133.00 times
P/BV: 1.66 times
EV/EBITDA: 65.50 times
Fabino Life Sciences operates in Pharmaceutical and Pharmaceutical And Wellness Products. The Issue is listed on BSE SME in Jan, 2022. Fabino Life Sciences IPO size was 3.24 with Issue price of 36.00 .
Merchant Banker(s) of Fabino Life Sciences IPO: Aryaman Financial Services Limited
Fabino Life Sciences IPO subscription was 6.93 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Fabino Life Sciences IPO listed at a listing price of 40.35 against the offer price of 36.00.
The current market price of Fabino Life Sciences is 25.00.
Why Us?
